Cargene Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cargene Therapeutics's estimated annual revenue is currently $1.6M per year.
- Cargene Therapeutics's estimated revenue per employee is $77,500
- Cargene Therapeutics's total funding is $19.2M.
Employee Data
- Cargene Therapeutics has 20 Employees.
- Cargene Therapeutics grew their employee count by -39% last year.
Cargene Therapeutics's People
| Name | Title | Email/Phone |
|---|
Cargene Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.9M | 63 | -24% | $15M | N/A |
#2 | $20M | 129 | -16% | $150M | N/A |
#3 | $3.7M | 48 | -6% | $53M | N/A |
#4 | $5.4M | 35 | -8% | N/A | N/A |
#5 | $3.6M | 23 | -18% | N/A | N/A |
#6 | $3.4M | 22 | 0% | N/A | N/A |
#7 | $5.4M | 35 | 6% | N/A | N/A |
#8 | $7.1M | 46 | -26% | N/A | N/A |
#9 | $36.1M | 233 | 4% | N/A | N/A |
#10 | $3.1M | 20 | -61% | N/A | N/A |
What Is Cargene Therapeutics?
Cargene is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics across a broad range of diseases and targeting a variety of organs and tissues. With sites in Singapore, China and USA, Cargene leverages our chemistry and biological insights to deliver clinically meaningful treatments. Cargene was founded by experienced biotech entrepreneurs XQ Lin, Dr. Yann Chong Tan, Professor Torsten Wuestefeld, and is advised by a world-class SAB including Professors Harvey Lodish, Roger Foo and Kosh Ray.
keywords:N/A
$19.2M
Total Funding
20
Number of Employees
$1.6M
Revenue (est)
-39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cargene Therapeutics News
In another transaction, Singapore-based biotech startup Cargene Therapeutics received an additional $3.9 million last week from its US-based...
Other Companies in Singapore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 20 | -75% | N/A |
#2 | $2.3M | 20 | 5% | N/A |
#3 | $4.3M | 20 | N/A | N/A |
#4 | $2.9M | 20 | N/A | N/A |
#5 | $2M | 20 | -5% | N/A |